Federal Circuit Vacates Knee Arthroplasty Patent Ruling Against DePuy Synthes

Introduction

In a significant procedural development for medical device patent litigation, the U.S. Court of Appeals for the Federal Circuit vacated and remanded the lower court’s decision in Rasmussen Instruments, LLC v. DePuy Synthes Products, Inc. (Case No. 23-1856), closed October 6, 2025. The appeal, originating from the District of Columbia and spanning 885 days, centered on two issued patents directed to knee arthroplasty systems and methods for optimally aligning and tensioning knee prostheses — a commercially vital technology segment in orthopedic surgery.

The Federal Circuit’s decision to vacate rather than affirm signals that critical legal questions remain unresolved, with potentially far-reaching consequences for medical device patent infringement litigation. For patent attorneys, in-house counsel at medtech companies, and R&D teams developing orthopedic implant systems, this case offers important lessons about claim construction, appellate strategy, and the risks of prematurely resolved infringement disputes. The outcome reinforces why knee arthroplasty patent litigation continues to be a high-stakes arena for both innovators and established device manufacturers.

Case Overview

The Parties

The Patents at Issue

Two U.S. patents formed the foundation of this infringement action, claiming inventions relating to **arthoplasty systems and methods for optimally aligning and tensioning a knee prosthesis**:

• • US 10,517,583 B2 — Systems and methods for optimally aligning and tensioning knee prostheses.
• • US 9,492,180 B2 — Systems and methods for optimally aligning and tensioning knee prostheses.

The Accused Products

DePuy Synthes’s knee arthroplasty instrumentation systems were accused of infringing the asserted patents. Given DePuy’s dominant market position in joint reconstruction, the commercial stakes were substantial, potentially affecting widely deployed surgical systems used in hundreds of thousands of knee replacement procedures annually.

Legal Representation

• • Plaintiff (Rasmussen): Jason M. Zucchi of Fish & Richardson LLP
• • Defendant (DePuy Synthes): Christopher Morrison of Jones Day

Litigation Timeline & Procedural History

The appeal was filed on May 5, 2023, with the Federal Circuit as the reviewing court — consistent with its exclusive jurisdiction over patent-related appeals from U.S. district courts. The District of Columbia served as the originating venue, a less conventional jurisdiction for patent infringement matters compared to the District of Delaware or Western District of Texas, which may reflect strategic venue considerations by the plaintiff.

The 885-day duration from filing to closure is notable, reflecting the complexity typical of Federal Circuit medical device patent appeals involving multi-patent claim construction disputes. No specific district court trial milestones, claim construction orders, or summary judgment details were disclosed in the available record. The case’s resolution at the appellate level — rather than through settlement or trial — underscores that substantive legal disagreements on core infringement or validity questions drove the litigation forward.

The Verdict & Legal Analysis

Outcome: Vacated and Remanded

The Federal Circuit issued a vacatur and remand — neither affirming the lower tribunal’s ruling in favor of either party nor rendering a final judgment on infringement. This outcome returns the case to the lower court or proceeding body for further proceedings consistent with the appellate court’s legal guidance.

Specific damages amounts were not disclosed in the available case record. No permanent injunctive relief outcome was specified in the reported data.

Verdict Cause Analysis

The case was designated an infringement action, meaning the core dispute involved whether DePuy Synthes’s knee arthroplasty products practiced the claims of the Rasmussen patents. A vacatur by the Federal Circuit in patent infringement cases most commonly arises from one or more of the following legal grounds:

• • Claim Construction Error: The Federal Circuit reviews claim construction *de novo*, making it the most frequent driver of vacaturs.
• • Infringement Analysis Insufficiency: If the lower tribunal’s infringement determination failed to properly apply the corrected claim construction to the accused products.
• • Procedural or Evidentiary Errors: Errors in admitted expert testimony, claim scope determinations, or summary judgment standards could support vacatur.

Legal Significance

The Federal Circuit’s role as the sole appellate court for patent matters makes every vacatur decision consequential. For knee arthroplasty patent litigation specifically, this outcome signals that:

1. Claim construction remains vigorously contested in surgical instrumentation patents.
2. Multi-patent assertions increase appellate complexity and the probability that at least one construction issue triggers remand.
3. Vacaturs preserve the plaintiff’s ability to reassert infringement under corrected legal standards.

Industry & Competitive Implications

The Rasmussen v. DePuy Synthes dispute reflects a broader pattern of IP assertion entity enforcement activity against established medical device manufacturers, particularly in high-revenue orthopedic segments. Total knee replacement is a multi-billion dollar global market, and patent rights covering alignment and tensioning methodology carry significant licensing value.

For DePuy Synthes and competing orthopedic manufacturers — including Zimmer Biomet, Stryker, and Smith & Nephew — this outcome reinforces the importance of proactive patent clearance for surgical instrumentation systems. Companies should monitor the remand proceedings closely, as the eventual infringement determination will establish important claim scope boundaries for arthroplasty alignment technology.

The case also highlights that patent holding companies continue to find viable enforcement opportunities in the medical device space, even against well-resourced defendants represented by elite litigation counsel. The Federal Circuit’s willingness to vacate rather than summarily affirm suggests that the underlying patents present genuine claim construction complexity worthy of further adjudication.